Summit Therapeutics annual depreciation and amortization
2018
2019
2020
2021
2022
2023
2024
2025
Summit Therapeutics Depreciation & Amortization Growth & History (SMMT)
Summit Therapeutics's depreciation and amortization was $146,000 for fiscal 2025.
View full Summit Therapeutics company overviewSummit Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $146,000 | $57,000 | +64.04% |
| 2024 | 2024-12-31 | $89,000 | −$109,000 | −55.05% |
| 2023 | 2023-12-31 | $198,000 | −$1.1M | −84.32% |
| 2022 | 2022-12-31 | $1.3M | −$84,000 | −6.24% |
| 2021 | 2021-12-31 | $1.3M | −$205,000 | −13.21% |
| 2020 | 2020-12-31 | $1.6M | $261,000 | +20.22% |
| 2019 | 2019-12-31 | $1.3M | — | — |
| 2018 | 2019-01-31 | $1.5M | — | — |
Summit Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $46,000 | $9,000 | +24.32% |
| Q1 2026 | 2026-03-31 | $44,000 | $19,000 | +76.00% |
| Q4 2025 | 2025-12-31 | $42,000 | — | — |
| Q3 2025 | 2025-09-30 | $42,000 | $22,000 | +110.00% |
| Q2 2025 | 2025-06-30 | $37,000 | $17,000 | +85.00% |
| Q1 2025 | 2025-03-31 | $25,000 | −$2,000 | −7.41% |
| Q3 2024 | 2024-09-30 | $20,000 | −$12,000 | −37.50% |
| Q2 2024 | 2024-06-30 | $20,000 | −$26,000 | −56.52% |
| Q1 2024 | 2024-03-31 | $27,000 | −$63,000 | −70.00% |
| Q3 2023 | 2023-09-30 | $32,000 | −$278,000 | −89.68% |
| Q2 2023 | 2023-06-30 | $46,000 | −$285,000 | −86.10% |
| Q1 2023 | 2023-03-31 | $90,000 | −$227,000 | −71.61% |
| Q3 2022 | 2022-09-30 | $310,000 | −$27,000 | −8.01% |
| Q2 2022 | 2022-06-30 | $331,000 | −$16,000 | −4.61% |
| Q1 2022 | 2022-03-31 | $317,000 | −$18,000 | −5.37% |
| Q3 2021 | 2021-09-30 | $337,000 | −$60,000 | −15.11% |
| Q2 2021 | 2021-06-30 | $347,000 | −$12,000 | −3.34% |
| Q1 2021 | 2021-03-31 | $335,000 | −$3,000 | −0.89% |
| Q3 2020 | 2020-09-30 | $397,000 | — | — |
| Q2 2020 | 2020-06-30 | $359,000 | — | — |
| Q1 2020 | 2020-03-31 | $338,000 | — | — |
Summit Therapeutics depreciation and amortization trends
Over the last five fiscal years, Summit Therapeutics's depreciation and amortization decreased from $1.6M to $146,000, a change of −$1.4M. The latest reported quarter, Q2 2026, shows $46,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Summit Therapeutics source filings ↗